Canaccord Genuity Reiterates a 'Buy' on Pernix Therapeutics (PTX); Tough Q1, But Thesis Remains Intact
Tweet
Share
E-mailGet Alerts PTX Hot Sheet
Price: $0.21 --0%
Rating Summary:
4 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
4 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Pernix Therapeutics (NYSE: PTX) price target lowered from $15 to $14.00.
Analyst, Randall Stanicky, said, "While Q1 results met a combination of macro headwinds from a light cough and cold season and well-understood softness in Natroba, we think much of the previous stock weakness into the quarter already reflected this. Importantly, the growth story remains intact with the anticipated launch of Omeclamox-Pak (gastroenterology) near-term and an active business development program providing important drivers. Overall, the risk/reward remains favorable and we continue to like PTX on a platform we think will drive robust growth."
For an analyst ratings summary and ratings history on Pernix Therapeutics click here. For more ratings news on Pernix Therapeutics click here.
Shares of Pernix Therapeutics closed at $7.51 yesterday.
Analyst, Randall Stanicky, said, "While Q1 results met a combination of macro headwinds from a light cough and cold season and well-understood softness in Natroba, we think much of the previous stock weakness into the quarter already reflected this. Importantly, the growth story remains intact with the anticipated launch of Omeclamox-Pak (gastroenterology) near-term and an active business development program providing important drivers. Overall, the risk/reward remains favorable and we continue to like PTX on a platform we think will drive robust growth."
For an analyst ratings summary and ratings history on Pernix Therapeutics click here. For more ratings news on Pernix Therapeutics click here.
Shares of Pernix Therapeutics closed at $7.51 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- Mizuho Reiterates Outperform Rating on Broadcom Limited (AVGO) Into EPS
- Keefe, Bruyette & Woods Resumes Toronto-Dominion Bank (TD:CN) (TD) at Market Perform
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
